Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: Part I. Conventional chemotherapeutic drugs

Journal of the American Academy of Dermatology

Volumn 71, Issue 2, 2014, Pages

  Reyes Habito, Claire Marie ^a   Roh, Ellen K ^b  

^a Los Banos Doctors Hospital and Medical Center   (Philippines)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cancer; chemotherapy; cutaneous reactions; cytotoxic therapy; drug hypersensitivity; rash

Indexed keywords

ALKYLATING AGENT; AMSACRINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; OXALIPLATIN; PEMETREXED; TEGAFUR; TENIPOSIDE; THIOTEPA; TOPOTECAN; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELL CYCLE PHASE; DERMATITIS; DERMATOLOGIST; DRUG HYPERSENSITIVITY; DRUG SAFETY; FIBROSIS; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; NAIL DISEASE; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; VESICULAR RASH;

CANCER; CHEMOTHERAPY; CUTANEOUS REACTIONS; CYTOTOXIC THERAPY; DRUG HYPERSENSITIVITY; RASH;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ERUPTIONS; EDUCATION, MEDICAL, CONTINUING; HUMANS; HYPERPIGMENTATION;

EID: 84904673472     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.04.014     Document Type: Review

References (93)

1. American Cancer Society web site. Chemotherapy principles: an in-depth discussion of the techniques and its role in cancer treatment. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/002995-pdf.pdf. Accessed April 11, 2012.
2. W.S. Susser, D.L. Whitaker-Worth, and J.M. Grant-Kels Mucocutaneous reactions to chemotherapy J Am Acad Dermatol 40 1999 367 398
3. J. Romankiewicz Cyclophosphamide and pigmentation Am J Hosp Pharm 31 1974 1074 1075
4. S. Yule, A. Pearson, and A. Craft Ifosfamide-induced hyperpigmentation Cancer 73 1994 240 241
5. M. Teresi, D. Murry, and A. Cornelius Ifosfamide-induced hyperpigmentation Cancer 71 1993 2873 2875
6. I.S. Rosman, B.M. Lloyd, R.J. Hayashi, and S.J. Bayliss Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation J Am Acad Dermatol 58 2008 575 578
7. T.D. Horn, R.A. Beveridge, M.J. Egorin, M.D. Abeloff, and A.F. Hood Observations and proposed mechanism of N,N',N'-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation Arch Dermatol 125 1989 524 527
8. B.W. Baker, C.L. Wilson, A.L. Davis, R.L. Spearing, D.N. Hart, and D.C. Heaton et al. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth Bone Marrow Transplant 7 1991 43 47
9. D.W. Lienesch, D.F. Mutasim, and R.R. Singh Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient: a complication of cyclophosphamide Lupus 12 2003 707 709
10. N.C. Manzione, A.W. Wolkoff, and S. Sassa Development of porphyria cutanea tarda after treatment with cyclophosphamide Gastroenterology 95 1988 1119 1122
11. G. Borroni, C. Vassallo, V. Brazzelli, S. Martinoli, M. Ardigò, and P.E. Alessandrino et al. Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma Am J Dermatopathol 26 2004 213 216
12. N. Heidary, H. Naik, and S. Burgin Chemotherapeutic agents and the skin: an update J Am Acad Dermatol 58 2008 545 570
13. N. Makrilia, E. Syrigou, I. Kaklamanos, L. Manolopoulos, and M.W. Saif Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review Met Based Drugs 2010 2010 pii: 207084. Epub 2010 Sept 20
14. K.M. Zanotti, L.A. Rybicki, A.W. Kennedy, J.L. Belinson, K.D. Webster, and B. Kulp et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy J Clin Oncol 19 2001 3126 3129
15. Z. Al-Lamki, P. Pearson, and N. Jaffe Localized cisplatin hyperpigmentation induced by pressure: a case report Cancer 77 1996 1578 1581
16. M.E. de Jonge, R.A. Mathôt, O. Dalesio, A.D. Huitema, S. Rodenhuis, and J.H. Beijnen Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy Bone Marrow Transplant 30 2002 593 597
17. M. Miteva, C. Misciali, P.A. Fanti, C. Vincenzi, P. Romanelli, and A. Tosti Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases Am J Dermatopathol 33 2011 345 350
18. C. Gooptu, T.J. Littlewood, P. Frith, C.C. Lyon, A.J. Carmichael, and S. Oliwiecki et al. Paraneoplastic pemphigus: an association with fludarabine? Br J Dermatol 144 2001 1255 1261
19. O. Yildiz, M. Ozguroglu, M.T. Yanmaz, H. Turna, S.G. Kursunoglu, and M. Antonov et al. Paraneoplastic pemphigus associated with fludarabine use Med Oncol 24 2007 115 118
20. A.M. Powell, S. Albert, N. Oyama, Y. Sakuma-Oyama, B. Bhogal, and M.M. Black Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans J Eur Acad Dermatol Venereol 18 2004 360 364
21. P. Meunier, S. Castaigne, J.N. Bastie, O. Chosidow, and S. Aractingi Cutaneous reactions after treatment with 2-chlorodeoxyadenosine Acta Derm Venereol 76 1996 385 386
22. C. Ganzel, M.E. Gatt, A. Maly, D. Ben-Yehuda, and N. Goldschmidt High incidence of skin rash in patients with hairy cell leukemia treated with cladribine Leuk Lymphoma 53 2012 1169 1173
23. A. Hendrick Purpuric rash following treatment with 2-chlorodeoxyadenosine Clin Lab Haematol 23 2001 67 68
24. M.S. Rossini, E.M. de Souza, M.L. Cintra, K.B. Pagnano, A.C. Chiari, and I. Lorand-Metze Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia J Eur Acad Dermatol Venereol 18 2004 538 542
25. C.Y. Chu, C.H. Yang, and H.C. Chiu Gemcitabine-induced acute lipodermatosclerosis-like reaction Acta Derm Venereol 81 2001 426 428
26. J. del Pozo, W. Martínez, M.T. Yebra-Pimentel, M. Almagro, C. Peña-Penabad, and E. Fonseca Linear immunoglobulin A bullous dermatosis induced by gemcitabine Ann Pharmacother 35 2001 891 893
27. A. Imen, K. Amal, Z. Ines, F. Sameh el, M. Fethi el, and G. Habib Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma Respir Med 100 2006 1463 1465
28. K.R. Sommers, K.M. Kong, D.T. Bui, J.P. Fruehauf, and R.F. Holcombe Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine Anticancer Drugs 14 2003 659 662
29. A. Brandes, U. Reichmann, L. Plasswilm, and M. Bamberg Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine - a report of three cases Anticancer Drugs 11 2000 15 17
30. A. Korniyenko, J. Lozada, A. Ranade, and G. Sandhu Recurrent lower extremity pseudocellulitis Am J Ther 19 2012 e141 e142
31. D. Bessis, B. Guillot, E. Legouffe, and J.J. Guilhou Gemcitabine- associated scleroderma-like changes of the lower extremities J Am Acad Dermatol 51 2 suppl 2004 S73 S76
32. P.A. Friedlander, R. Bansal, L. Schwartz, R. Wagman, J. Posner, and N. Kemeny Gemcitabine-related radiation recall preferentially involves internal tissue and organs Cancer 100 2004 1793 1799
33. J.J. Rusthoven, E. Eisenhauer, C. Butts, R. Gregg, J. Dancey, and B. Fisher et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 17 1999 1194
34. B. Eguia, A.M. Ruppert, J. Fillon, A. Lavolé, V. Gounant, and C. Epaud et al. Skin toxicities compromise prolonged pemetrexed treatment J Thorac Oncol 6 2011 2083 2089
35. E. Frouin, G. Sebille, S. Freudenberger, B. Menecier, E. Quoix, and B. Cribier et al. Asteatotic eczema ('eczema craquelé') with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed Br J Dermatol 166 2012 1359 1360
36. D. Schallier, L. Decoster, and J. de Greve Pemetrexed-induced yperpigmentation of the skin Anticancer Res 31 2011 1753 1755
37. G. Lopes, V. Vincek, and L.E. Raez Pemetrexed-associated urticarial vasculitis Lung Cancer 51 2006 247 249
38. C.A. Dasanu, P.H. Wiernik, J. Vaillant, and D.T. Alexandrescu A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer Skinmed 6 2007 95 96
39. J. Bosch-Barrera, M. Gaztañaga, J. Ceballos, J.L. Pérez-Gracia, J.M. López-Picazo, and J. García-Foncillas et al. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer Onkologie 32 2009 580 584
40. A. Bracke, E. Van Marck, and J. Lambert Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction Clin Exp Dermatol 34 2009 337 339
41. J. Hureaux, Y. Le Guen, C. Tuchais, L. Savary, and T. Urban Radiation recall dermatitis with pemetrexed Lung Cancer 50 2005 255 258
42. M. Malet-Martino, and R. Martino Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review Oncologist 7 2002 288 323
43. T. Skacel, R. von Moos, and R. Dummer Topoisomerase-interacting agents M.E. Lacouture, Dermatologic principles and practice in oncology: conditions of the skin, hair and nails in cancer patients 1st ed. 2014 Wiley-Blackwell Philadelphia (PA) 170 183
44. A. Rosen, I. Amitay-Laish, and M. Lacouture Management algorithms for dermatologic adverse events M.E. Lacouture, Dermatologic principles and practice in oncology: conditions of the skin, hair and nails in cancer patients 1st ed. 2014 Wiley-Blackwell Philadelphia (PA) 367 383
45. C.J. Fabian, R. Molina, M. Slavik, S. Dahlberg, S. Giri, and R. Stephens Pyridoxine therapy for palmar-plantar eythrodysesthesia associated with continuous 5 fluorouracil infusion Invest New Drugs 8 1990 57 63
46. V. von Gruenigen, H. Frasure, N. Fusco, R. DeBernardo, E. Eldermire, and S. Eaton et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients Cancer 116 2010 4735 4743
47. R. von Moos, B.J. Thuerlimann, M. Aapro, D. Rayson, K. Harrold, and J. Sehouli et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts Eur J Cancer 44 2008 781 790
48. R.E. Sanborn, and D.A. Sauer Cutaneous reactions to chemotherapy: commonly seen, less described, little understood Dermatol Clin 26 2008 103 119
49. C. Twelves Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials Eur J Cancer 38 suppl 2 2002 15 20
50. J.Y. Douillard, P.M. Hoff, J.R. Skillings, P. Eisenberg, N. Davidson, and P. Harper et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 2002 3605 3616
51. G. Villalón, J.M. Martín, M.I. Pinazo, L. Calduch, V. Alonso, and E. Jordá Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine Am J Clin Dermatol 10 2009 261 263
52. E. Llistosella, A. Codina, R. Alvarez, R.M. Pujol, and J.M. de Moragas Tegafur-induced acral hyperpigmentation Cutis 48 1991 205 207
53. J.E. Do, and Y.C. Kim Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? Clin Exp Dermatol 32 2007 519 521
54. A. Jucglà, G. Sais, M. Navarro, and J. Peyri Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur Arch Dermatol 131 1995 364 365
55. C. Sauter, A. Saborowski, and H.M. Ockenfels Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer (in German) Hautarzt 58 2007 619 622
56. S.D. Lee, H.J. Kim, S.J. Hwang, Y.J. Kim, S.H. Nam, and B.S. Kim Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report Korean J Intern Med 22 2007 109 112
57. B. Vasudevan An unusual case of capecitabine hyperpigmentation: is hyperpigmentation a part of hand-foot syndrome or a separate entity? Indian J Pharmacol 42 2010 326 328
58. T. Paravar, and S.R. Hymes Longitudinal melanonychia induced by capecitabine Dermatol Online J 15 2009 11
59. G.Y. Chen, Y.H. Chen, M.M. Hsu, C.J. Tsao, and W.C. Chen Onychomadesis and onycholysis associated with capecitabine Br J Dermatol 145 2001 521 522
60. F. Revenga Cutaneous side-effects caused by tegafur Int J Dermatol 38 1999 955 957
61. J.S. Hague, and A. Ilchyshyn Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer Clin Exp Dermatol 32 2007 102 103
62. A. Willey, E.J. Glusac, and J.L. Bolognia Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer J Am Acad Dermatol 47 2002 453
63. M. Krathen, J. Treat, and W.D. James Capecitabine induced inflammation of actinic keratoses Dermatol Online J 13 2007 13
64. N. Ghosal, and V. Misra A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon Clin Oncol (R Coll Radiol) 21 2009 632
65. F. Merlin, T. Prochilo, B. Kildani, C. Lombardi, G. Pasolini, and F. Bonetti et al. Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine Int J Colorectal Dis 23 2008 715 716
66. A. Adachi, H. Nagai, and T. Horikawa Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions Dermatology 214 2007 85 88
67. E. Piqué-Duran, M.J. Pérez-Díaz, and J.A. Pérez-Cejudo Pyogenic granuloma-like lesions caused by capecitabine therapy Clin Exp Dermatol 33 2008 652 653
68. V. Piguet, and L. Borradori Pyogenic granuloma-like lesions during capecitabine therapy Br J Dermatol 147 2002 1270 1272
69. J. Dalmau, E. Roé, L. Puig, and A. Alomar Granulomatous septal panniculitis associated with capecitabine (Xeloda) J Eur Acad Dermatol Venereol 22 2008 121 122
70. J. Mangana, M.C. Zipser, C. Conrad, P.A. Oberholzer, A. Cozzio, and A. Knuth et al. Skin problems associated with pegylated liposomal doxorubicin - more than palmoplantar erythrodysesthesia syndrome Eur J Dermatol 18 2008 566 570
71. M. Salzberg, B. Thurlimann, U. Hasler, G. Delmore, A. von Rohr, and A. Thurlimann et al. Pegylated liposomal doxorubicin(caelyx) in metastatic breast cancer: a community-based observation study Oncology 72 2007 147 151
72. M. Lotem, A. Hubert, O. Lyass, M.A. Goldenhersh, A. Ingber, and T. Peretz et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin Arch Dermatol 136 2000 1475 1480
73. T. Yamamoto Bleomycin and the skin Br J Dermatol 155 2006 869 875
74. R. Wolf, and D. Wolf Bleomycin-induced flagellate dermatitis Int J Dermatol 50 2011 546 547
75. M. Pechère, G.B. Zulian, J.J. Vogel, M. Jeanprêtre, B. Hirschel, and J.H. Saurat Fingertip necrosis during chemotherapy with bleomycin, vincristine and methotrexate for HIV-related Kaposi's sarcoma Br J Dermatol 134 1996 378 379
76. C. Garbe Antimicrotubule agents M.E. Lacouture, Dermatologic principles and practice in oncology: conditions of the skin, hair and nails in cancer patients 1st ed. 2014 Wiley-Blackwell Philadelphia (PA) 208 214
77. C.P. Lau, P. Hui, and T.C. Chan Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review Chin Med J (Engl) 124 2011 2559 2560
78. C. Bokemeyer, C. Lampe, M. Heneka, M. Schabet, M. Bamberg, and L. Kanz Paclitaxel-induced radiation recall dermatitis Ann Oncol 7 1996 755 756
79. M.D. Piroth, R. Krempien, M. Wannenmacher, and D. Zierhut Radiation recall dermatitis from docetaxel Onkologie 25 2002 438 440
80. P.R. Cohen Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer J Drugs Dermatol 8 2009 61 64
81. B.N. Akay, E. Unlu, A. Buyukcelik, and A. Akyol Photosensitive rash in association with porphyrin biosynthesis possibly induced by docetaxel and trastuzumab therapy in a patient with metastatic breast carcinoma Jpn J Clin Oncol 40 2010 989 991
82. M. Chen, A.N. Crowson, M. Woofter, M.B. Luca, and C.M. Magro Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases J Rheumatol 31 2004 818 820
83. I. Kupfer, X. Balguerie, P. Courville, P. Chinet, and P. Joly Scleroderma-like cutaneous lesions induced by paclitaxel: a case study J Am Acad Dermatol 48 2003 279 281
84. B.B. Mishra, and V.K. Tiwari Natural products: an evolving role in future drug discovery Eur J Med Chem 46 2011 4769 4807
85. E. Rowinsky Microtubule-targeting natural products D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.C. Bast Jr. T.S. Gansler, J.F. Holland, Holland-Frei cancer medicine 6th ed. 2003 BC Decker Hamilton (ON)
86. H. Nakashima, M. Fujimoto, and K. Tamaki Cutaneous reaction induced by vincristine Br J Dermatol 153 2005 225 226
87. D. Arias, L. Requena, A. Hasson, M. Gutierrez, M. Domine, and L. Martin et al. Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine J Cutan Pathol 18 1991 344 346
88. P.M. Hoff, V. Valero, N. Ibrahim, J. Willey, and G.N. Hortobagyi Hand-foot syndrome following prolonged infusion of high doses of vinorelbine Cancer 82 1998 965 969
89. Y. Pommier DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition Chem Rev 109 2009 2894 2902
90. J. Moukharskaya, and C. Verschraegen Topoisomerase 1 inhibitors and cancer therapy Hematol Oncol Clin North Am 26 2012 507 525
91. S. Marsh, and J.M. Hoskins Irinotecan pharmacogenomics Pharmacogenomics 11 2010 1003 1010
92. S. Ezoe Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor Int J Environ Res Public Health 9 2012 2444 2453
93. K. Marigny, F. Aubin, G. Burgot, E. Le Gall, and V. Gandemer Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Cancer Chemother Pharmacol 55 2005 244 250